Publications by authors named "Daniela Cipu"
Article Synopsis
- - The study explores the link between renal abscesses and acute acalculous cholecystitis, noting that proximity of the gallbladder and kidney may lead to complications if infection spreads from the kidney to the gallbladder.
- - Researchers conducted a retrospective analysis of 67 patients, mostly females, using ultrasound and various lab tests to assess the connection between renal abscesses and gallbladder issues.
- - Out of the patients, 11.94% showed signs of cholecystitis, with all cases of acute acalculous cholecystitis exhibiting sepsis but preserved renal function; timely antibiotic treatment led to positive outcomes without complications.
Article Synopsis
- - Dapagliflozin treatment in type 2 diabetes (T2D) patients leads to decreased epicardial fat volume (EFV), which is linked to better heart function, but EFV assessments are not common due to cost and radiation concerns.
- - A study involving 52 patients on dapagliflozin measured various factors like atherogenic index and visceral fat to find biomarkers that predict EFV reduction after six months of treatment.
- - The results indicated that certain biomarkers (AIP, CRR, TyG) correlate with greater EFV reductions; TyG proved to be the most effective in predicting these changes.
Patients with type 2 diabetes (T2DM) are at high risk of developing cardiovascular disease and heart failure (HF), both with preserved and reduced ejection fraction of the left ventricle. Previous research demonstrated that dapagliflozin treatment is associated with the remission of type 1 diastolic dysfunction (DD1) in patients with T2DM. The main aim of this study was to evaluate the possible baseline predictors associated with the remission of DD1 in patients with T2D after one year of dapagliflozin treatment.
View Article and Find Full Text PDFPurpose: The aim of this study was to assess the dynamics of epicardiac adipose tissue (EAT) thickness and total volume as well as that of systolic and diastolic dysfunction in a group of patients with type 2 diabetes (T2D) after initiation of sodium glucose co-transporter 2 (SGLT 2) inhibitors therapy.
Patients And Methods: This prospective, observational study included 53 patients with T2D who received SGLT-2 inhibitors for 24 weeks. In all patients, echocardiographic screening for EAT, systolic and diastolic dysfunction and non-contrast computed tomography scans were performed, both before and after 24 weeks of SGLT-2 inhibition.